Abstract
Background: Glycan-binding proteins are widely distributed in human and play an essential role in biological processes. Their involvements in inflammatory and immune responses make it increasingly likely that the glycan-binding proteins may represent valuable therapeutic targets.
Objective: The current review aims to provide information on recent advancements in clinical developments of antibodies against glycan-binding proteins as potential targets.
Results and Conclusion: There are several therapeutic antibodies being developed targeting glycanbinding proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies have provided great promises in therapeutic targeting of more glycan-binding proteins for treating multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies.
Keywords: Glycan-binding proteins, lectins, antibodies, clinical development, inflammation, autoimmune diseases, hematological malignancies.
Current Drug Targets
Title:Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins
Volume: 19 Issue: 13
Author(s): Qun Zhou*
Affiliation:
- Protein Engineering, Biologics Research, Sanofi, Framingham, MA, 01701,United States
Keywords: Glycan-binding proteins, lectins, antibodies, clinical development, inflammation, autoimmune diseases, hematological malignancies.
Abstract: Background: Glycan-binding proteins are widely distributed in human and play an essential role in biological processes. Their involvements in inflammatory and immune responses make it increasingly likely that the glycan-binding proteins may represent valuable therapeutic targets.
Objective: The current review aims to provide information on recent advancements in clinical developments of antibodies against glycan-binding proteins as potential targets.
Results and Conclusion: There are several therapeutic antibodies being developed targeting glycanbinding proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies have provided great promises in therapeutic targeting of more glycan-binding proteins for treating multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies.
Export Options
About this article
Cite this article as:
Zhou Qun*, Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins, Current Drug Targets 2018; 19 (13) . https://dx.doi.org/10.2174/1389450119666180308144313
DOI https://dx.doi.org/10.2174/1389450119666180308144313 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Apoptotic Effects of Some Tetrahydronaphthalene Derivatives on K562 Human Chronic Myelogenous Leukemia Cell Line
Anti-Cancer Agents in Medicinal Chemistry Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity
Anti-Cancer Agents in Medicinal Chemistry The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Anal Carcinoma
Current Cancer Therapy Reviews Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design From Systems Biology to Systems Pathology: A New Subspecialty in Diagnostic and Personalized Medicine
Current Pharmacogenomics and Personalized Medicine CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors
Current Cancer Drug Targets Targeting the IL-6 Pathway in Multiple Myeloma and its Implications in Cancer-Associated Gene Hypermethylation
Medicinal Chemistry Cell Therapies for IBD: What Works?
Current Drug Targets Regulation of Autophagy by Sphingolipids
Anti-Cancer Agents in Medicinal Chemistry Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment
Current Drug Targets Obesity and Cancer: Biological Links and Treatment Implications
Current Cancer Drug Targets Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets